Encorium Group Inc (fka ENCO)

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Renee

11/10/14 9:40 AM

Post #131

Re: #130: @Renee - ENCO SEC Suspension:

ENCO revoked:

http://www.sec.gov/litigation/admin/2014/34-73567.pdf

Renee

08/06/14 9:34 AM

Post #130

ENCO SEC Suspension:

http://www.sec.gov/litigation/suspensions/2014/34-72769.pdf

Order:

http://www.sec.gov/litigation/suspensions/2014/34-72769-o.pdf

Admin Proceeding:

http://www.sec.gov/litigation/admin/2014/34-72770.pdf

thesmalls

12/04/13 10:16 PM

Post #129

four significant trading days this year. back in early march there was a day where 1.5MM shares traded and then later in march a day where 400K shares traded. then in early april a day with 350K shares. then nothing until 10/4 when 3.5MM shares traded at $0.017. the last share count was only 5.27MM shares and that passes that amount. even if the earlier trading in the year was a hedge fund yanking things around - the 3.5MM was clearly someone securing controlling interest in the shell. the question becomes - why?

i wondered a long time ago if the BK was just a means to recapitalize later and buy up existing stock to start again. could be the former split entity in sweden will reemerge as a public company by taking over the shell. would definitely give the primary investor a direct path to recover rather handsomely the millions he was plowing into the company while it was tanking.

i certainly am not convinced to buy but i am rather intrigued on what the play is here.

thesmalls

10/23/13 4:03 PM

Post #128

there is no company behind this ticker. it is simply a shell. the company went bankrupt about 18-24 months ago. prior to that they had completed a reverse split that brought the total share count down to around 5MM shares. now - hard to say if there are more than that now but there have been no filings.

someone/entity bought 3.5MM beginning of OCT. someone is taking over the shell for another entity. whether or not that will be a legitimate company looking to raise capital in the equity markets and short circuiting the normal IPO process - who knows. it is certainly cheaper buying a shell when you can acquire controlling interest for $0.003 * 3.5MM shares instead of the normal route.

my guess is now that it is obvious someone wants this company, there is a rush for the few remaining outstanding shares which is where the run up is occurring. right now - this company does NOTHING. it is simply a shell.

my guess is there will probably be a registration statement with the SEC within 30 days along witha name change signifying the change in control and what the new entity is. only then will it be known if there is any value here.

ClearlyStocks Free

10/23/13 3:46 PM

Post #127

Decided to sell .17 850% gain. Not to shabby

Thank you :)))))

ClearlyStocks Free

10/23/13 3:38 PM

Post #126

Easy to $1? .25 is up!

ClearlyStocks Free

10/23/13 2:04 PM

Post #125

Re: #124: @grunt1 - how much further

Someone wants this up real bad. .11 again. Might go much higer

grunt1

10/21/13 7:27 AM

Post #124

Re: #123: @ClearlyStocks - Hit .15! Wow! Going much further

how much further

ClearlyStocks Free

10/18/13 10:37 AM

Post #123

Hit .15! Wow! Going much further

ClearlyStocks Free

10/07/13 9:35 AM

Post #122

Slowly going...

SkipDawg

10/05/13 8:26 PM

Post #121

Re: #120: @ClearlyStocks - Looking gppd

Anybody know companies website? Hmmm...

ClearlyStocks Free

10/04/13 11:07 AM

Post #120

Looking gppd

kranthikumar Free

10/04/13 9:59 AM

Post #119

ENCO is smells like a winner

ClearlyStocks Free

10/04/13 9:40 AM

Post #118

Seams like 1000+% coming

thesmalls

03/09/13 10:16 PM

Post #117

Re: #116: @thesmalls - I Havent sold yet. At this point, there

i ended up selling just under 20K in december of last year for the loss. i still hold close to 50K. this was by far the biggest loss i ever had. the way the largest shareholder was plowing money into this made me think they were on the verge of shaking the monkey.

i was not a fan of their M&A activity once Borrow (former CEO) was forced out. looking back i should have been easing out when the other major shareholders were bailing while the primary was doubling down.

that being said - they still had significant contracts and pipeline when they declared BK. i have been trying to research what became of these as it seems that the company could reemerge due to the IP around clinical trial studies.

thesmalls

08/02/12 1:17 PM

Post #116

Re: #115: @airbus300 - I sold my 300 or so shares for

I Havent sold yet. At this point, there is no advantage until I need the write off. More than likely - the shares will be accumulated for the trading seat or to continue as a different entity

airbus300

07/14/12 4:29 PM

Post #115

Re: #114: @thesmalls - anyone still following this stock or have educated

I sold my 300 or so shares for 1.6 cents per share. 99 percent loss.

thesmalls

07/09/12 10:23 AM

Post #114

Re: #111: @GreyGoose_69 - PPS back over $4!!!! Watch out folks! We

anyone still following this stock or have educated guesses on what happens next following the BK announcement? the company remains intact even though most of it is defunct. what is the purpose? there were several key investors that put a lot of money into this company at precarious times. either they knew a lot more about what was going on than the retail guys or were really stupid. hard to imagine their track record fo success and plow money into something like this unless there was a longer term plan.

the primary investor ended up buying up most of the shares that were not secured by existing shareholders in the rights offering several years ago. dropped close to $3MM and the share price had already tanked.

i have posted several times through the years on yahoo that i thought the share price was left to languish so it could be taken private or bought up, consolidated, and then do a new secondary. either the business environment dramatically changed or they planned this BK ahead of time.

i dont know if Kai was incompetent, shrewd, or an arrogant prick. however, it was nothing but downhill after he ousted Borrow and made himself CEO. since he was the largest shareholder - my guess is incompetence and arrogance. his conference calls were a joke and he could not answer straight forward business questions from analysts. he then stopped having them and the stock tanked.

that being said - does anyone know what value resides? is it just the trading seat on the exchange?

Penny Roger$ Free

04/15/12 8:49 AM

Post #113

Re: #107: @GreyGoose_69 - I'm doing ENCO today! Great news folks!

GreyGoose_69 Free

05/10/10 4:37 PM

Post #112

Kai Lindevall, Chief Executive Officer, of the Company stated, "This is the most significant break-through to date in our business development efforts in the Asian market. We are very pleased to have been awarded these landmark studies for this major high-tech company. To be selected as a preferred provider is the best benchmark we could imagine with which to measure our success in Asia. In addition, we have recently seen a significant increase in the number of requests for proposals and are seeing signs that the market appears to be regaining some of its pre-recession vibrancy, particularly in the case of small to medium sized biopharmaceutical companies, which are a key market for the Company."

GreyGoose_69 Free

05/10/10 3:14 PM

Post #111

PPS back over $4!!!! Watch out folks! We are taking off!

GreyGoose_69 Free

05/10/10 1:59 PM

Post #110

Re: #96: @MrGekko - Will see $3.00 on Monday

This is the bottom IMO...Should move up from here! I think the news was stellar today!

GreyGoose_69 Free

05/10/10 1:58 PM

Post #109

http://finance.yahoo.com/q/is?s=enco

GreyGoose_69 Free

05/10/10 1:53 PM

Post #108

http://www.thestreet.com/_yahoo/story/10751863/1/encorium-group-rock-of-age-midday-volume-plays.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA

GreyGoose_69 Free

05/10/10 11:46 AM

Post #107

I'm doing ENCO today! Great news folks!

califax

04/20/10 10:57 AM

Post #106

Outstanding at March 31, 2010: 3,388,173

http://ih.advfn.com/p.php?pid=nmona&cb=1271775364&article=42441796&symbol=ENCO

califax

04/20/10 10:19 AM

Post #105

Encorium Reports Fourth Quarter and Year End 2009 Financial Results

Date : 04/19/2010 @ 5:15PM
Source : PR Newswire
Stock : Encorium Grp. (MM) (ENCO)

http://ih.advfn.com/p.php?pid=nmona&article=42441954&symbol=ENCO

PR Newswire

WAYNE, Pa., April 19

WAYNE, Pa., April 19 /PRNewswire-FirstCall/ --

Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced its financial results for the fourth quarter and year ended December 31, 2009.

As previously announced, on July 16, 2009 the Company sold substantially all of the assets relating to its U.S. line of business to Pierrel Research USA, Inc., the result of which the Company no longer has any employees or significant operations in the United States. Due to this sale, for the three and 12 months ended December 31, 2009 and 2008, the results of the U.S. business have been presented as discontinued operations in the Company's consolidated financial statements.

2009 Fourth Quarter Financial Results

Net revenue for the fourth quarter of 2009 was $4.4 million, a decrease of 21.4% from $5.6 million for the fourth quarter of 2008. The decrease in net revenues was primarily attributable to overall reductions in clinical trial activity, approximately $491 thousand of revenue recognized on contracts that completed in 2008 off set by favorable foreign currency fluctuations of $480 thousand for the three months ended December 31, 2009. The Company had a consolidated backlog at December 31, 2009 from continuing operations of $17.1 million which included approximately $12.3 million of new business wins in 2009 compared to a backlog of $23.8 million at December 31, 2008.

Direct expenses for the fourth quarter of 2009 were $3.3 million, or 74.9% of net revenues, compared to $3.6 million, or 64.4% of net revenues, for the comparable prior year period. The decrease in direct expenses was primarily the result of reductions in staff and subcontractors utilized on active clinical studies being conducted and approximately $341 thousand of unfavorable foreign currency fluctuation.

Selling, general, and administrative expenses (SG&A) was $1.7 million, or 38.5% of net revenue, for the three months ended December 31, 2009, compared to $2.2 million, or 39.2% of net revenue, for the three months ended December 31, 2008.

Loss from continuing operations decreased to $558 thousand or $(0.18) per diluted share for the fourth quarter of 2009, from a net loss of $12.6 million, or $(4.92) per diluted share, in the fourth quarter of 2008.

2009 Full Year Financial Results

Net revenue for the twelve months ended December 31, 2009 decreased to $17.9 million as compared to $22.3 million for the twelve months ended December 31, 2008. The decrease in revenue was primarily due to a decrease in the number of contracts and related contract values of active clinical studies along with $1.1 million of unfavorable currency fluctuations.

Direct expenses for the year ended December 31, 2009 were $12.6 million compared to $14.6 million for the year ended December 31, 2008. Despite reduced staffing and subcontractor costs and a favorable currency fluctuation of $1.1 million, direct expenses as a percent of net revenue increased to 70.3% from 65.6% in the prior year due to lower net revenues. SG&A expenses for 2009 were $8.1 million, or 45.4% of net revenue, compared to $9.0 million, or 40.5% of net revenue, for 2008. Of the $916 thousand decrease in SG&A, approximately $581 thousand was attributable to favorable foreign currency fluctuations, with the remainder a result of reductions in staff and overhead.

Depreciation and amortization expense for 2009 declined to $380 thousand compared to $1.3 million for 2008, primarily as a result of intangibles related to the Encorium OY acquisition becoming fully amortized.

The Company reported a net loss from continuing operations for the twelve months ended December 31, 2009 of $3.1 million, or $(1.16) per diluted share, as compared to a net loss from continuing operations of $16.9 million, or $(6.57) per diluted share for the twelve months ended December 31, 2008. Included in the 2008 results is a non-cash $14.4 million, or ($0.70) per share, asset impairment charge related to the Company's intangible assets, which includes a $1.9 million non-cash interim asset impairment charge recorded by the Company during the third quarter of 2008 as well as the $12.5 million charge taken in the fourth quarter.

Financial Position, Going Concern and Potential Delisting

Encorium's balance sheet at December 31, 2009 reflected cash and cash equivalents of $197 thousand and stockholders' equity of $2.3 million. Our net cash used in operations for the year ended December 31, 2009 was approximately $8.0 million. The Company's latest financials have been prepared on a going concern basis. The report of Encorium's independent registered public accounting firm, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 19, 2010, contains a paragraph that indicates that, while the Company's financial statements have been prepared on a going concern basis, there is substantial doubt about its ability to continue as a going concern, and that no adjustments have been made to the financial statements that might result from the outcome of this uncertainty.

We anticipate that will meet our cash requirements at least into March of 2011, assuming we are able to fully implement our current costs cutting initiatives, we are able to win additional contracts and we are able to maintain our current customer contracts. In the event we are unable to do so, in order for the Company to continue as a going concern we will be required to obtain additional capital from external sources or significantly reduce our operating costs, which may include the cessation of operations in some countries.

Encorium currently fails to meet NASDAQ's $2.5 million minimum stockholders' equity requirement for continued listing and may not be able to meet the other listing requirements in the future. The Company anticipates that a delisting action will be brought against it for failure to comply with the requirement. If a delisting action is brought, the Company may request a hearing before the NASDAQ Listing Qualifications Panel. Such request would stay any delisting determination by the NASDAQ Listing Qualifications Staff and the Company's common stock would remain listed on NASDAQ pending a formal determination by the Panel. However, there can be no assurances that the Panel will grant such request.

Dr. Kai Lindevall, executive chairman stated, "We are very pleased with the cost cutting initiatives that we have put in place. While additional financing is likely necessary, we believe our experience and capabilities in the vaccine field coupled with the recent new awards in this area demonstrate the long term potential we have to grow into a leading vaccine franchise with expertise in regulatory consultancy and strategic trial planning."

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process.

This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the risk that we may not have sufficient funds to operate our business; (ii) our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; (xiii) uncertainties regarding the availability of additional capital; and (xiv) uncertainties regarding the continued listing of our common stock on NASDAQ. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Company Annual Report on Form 10-K for the year ended December 31, 2009 for a more complete discussion of factors which could cause our actual results and financial position to change.

--financial tables ...

califax

04/19/10 11:19 AM

Post #104

Re: #101: @califax - 19th – 22nd of April 2010 - World_Vaccine_Congress_Washington_DC

CONGRESS DAY 1 - 19th April: FEDERAL AND GLOBAL IMMUNISATION FOCUS

http://www.terrapinn.com/2010/wvcdc/programme.stm

16.10
How outsourcing can enhance and speed up development towards licensure of vaccines

* What influence will the new emphasis of the World Health Organization have on regional prioritization on immunization program development
* Case Study I: Why is Finland such an excellent choice to conduct pediatric vaccines studies?
* Case Study II: Turkey – a new European country to conduct vaccine studies?
* Case Study III: What are the additional challenges in conducting such studies in emerging countries, e.g. Philippines?
* The vaccine CRO of the Future

Dr Georg Lautscham,
Director Business Development, Encorium, Encorium

califax

04/18/10 6:34 AM

Post #103

Encorium receives French Research Tax Credit approval

05 February 2010
http://www.encorium.com/news/pdfs/Encorium_French_Research_Tax_Credit_Approval_5-Feb-2010.pdf

The French Ministry for Higher Education and Research has approved Encorium’s application to conduct R&D activities on behalf of private companies.

This approval allows companies subject to the French General Tax Code to take advantage of the research and development tax credit offered by France. As a result, Encorium’s current and future French customers will be able to benefit from the CIR from 2009 to 2011 by which time the approval is up for renewal.

Research and Development (R&D) tax credits have emerged as one of the preferred tools for promoting and expanding R&D spending. In France the pharmaceuticals industry benefits from one of the best R&D tax-credit system in Europe, which reimburses up to 50% of R&D costs in the first year.

Dr. Kai Lindevall, CEO stated, “We are delighted to announce that our application has been successful. This approval will help our existing and future customers to take advantage of the R&D tax credit enabling them to invest more money into the development of their products. This is yet another example of Encorium’s recognition as a high quality CRO and will further strengthen our market position in France.”
http://www.encorium.com

califax

04/17/10 7:02 AM

Post #102

Re: #92: @califax - BARCHART -

BARCHART -

http://quote.barchart.com/texpert.asp?sym=enco&code=BSTK

Composite Indicator
Trend Spotter TM Buy

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Buy

Short Term Indicators Average: 100% - Buy
20-Day Average Volume - 1588720

Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 100% - Buy
50-Day Average Volume - 646404

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Sell

Long Term Indicators Average: 33% - Buy
100-Day Average Volume - 348751

Overall Average: 88% - Buy

Price Support Pivot Point Resistance
5.46 3.78 5.50 7.22

califax

04/17/10 6:00 AM

Post #101

Re: #81: @califax - Encorium is present at World Vaccine Congress Washington

19th – 22nd of April 2010 - World_Vaccine_Congress_Washington_DC

Please visit our Vaccine page at: www.encorium.com/vaccines

http://www.terrapinn.com/2010/wvcdc/index.stm

Gold Sponsor: i.e. ENCORIUM
http://www.terrapinn.com/2010/wvcdc/confspon.stm

Speakers
http://www.terrapinn.com/2010/wvcdc/speakerList.stm

... Dr George Lautscham,
Director Business Development, Encorium

califax

04/16/10 11:04 AM

Post #100

Stock Alert for Encorium Group Inc. Issued by MicroStockProfit

Date : 04/16/2010 @ 6:50AM
Source : GlobeNewswire Inc.
Stock : (ENCO)

http://ih.advfn.com/p.php?pid=nmona&article=42409451&symbol=ENCO

DALLAS, April 16, 2010
GLOBE NEWSWIRE
MicroStockProfit.com announces an investment report featuring Encorium Group Inc. (Nasdaq:ENCO). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/ENCO

Encorium Group Inc. (ENCO) is a clinical research organization (CRO), which is engaged in the design and management of clinical trials for the pharmaceutical, biotechnology and medical device industries. The Company's clients consist of companies in the pharmaceutical, biotechnology and medical device industries. The Company offers a range of clinical research and development services supporting phase I through phase IV clinical trials, such as strategic trial planning, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, quality assurance, outsourcing of clinical staff and medical device certification in the European Union. The Company's services include study protocol design, clinical trials management, global data management services, biostatistics, medical and regulatory affairs, quality assurance and compliance, and medical report writing.

In the report, the analyst notes:

"ENCO recently announced that it will file a Form 12b-25 with the Securities and Exchange Commission, which will provide the Company with a 15-calendar day extension for filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2009. The Company's independent registered accounting firm has not completed its audit of the Company's financial statements and has not provided its report and consent for the Company's Annual Report. The Company will file its Form 10-K as soon as its independent registered accounting firm provides its report on those financial statements and its consent."

To read the entire report visit: www.microstockprofit.com/ads/ENCO

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com.

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: MicroStockProfit.com

Brian Johnson

1-888-307-2850

info@microstockprofit.com

califax

04/15/10 12:30 PM

Post #99

wink -

airbus300

04/15/10 10:32 AM

Post #98

Re: #96: @MrGekko - Will see $3.00 on Monday

Looks like $4.50.

airbus300

04/15/10 10:31 AM

Post #97

Re: #90: @petermic - I'm not familiar with ENCO particularly, but I

Sure is holding up well.

MrGekko

04/09/10 2:52 PM

Post #96

Will see $3.00 on Monday

CHA$E

04/06/10 2:24 PM

Post #95

WOWZER...HOW MUCH MORE?!?! Awesome VERTICAL climb...might hold as well. ;)

califax

04/01/10 2:43 PM

Post #94

Notification that Annual Report will be submitted late (NT 10-K)

Date : 04/01/2010 @ 2:00PM
Source : Edgar (US Regulatory)
Stock : (ENCO)

http://ih.advfn.com/p.php?pid=nmona&cb=1270147231&article=42235080&symbol=N^ENCO

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Philip L. Calamia 484-588-5400
(Name) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). x Yes ¨ No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? x Yes ¨ No

califax

03/31/10 10:59 AM

Post #93

Liberty Analytics Co. Initiates Independent Research Coverage on Encorium Group, Inc.

Date : 03/31/2010 @ 9:15AM
Source : GlobeNewswire Inc.
Stock : (ENCO)

http://ih.advfn.com/p.php?pid=nmona&article=42206740&symbol=ENCO

Liberty Analytics Co., a leading provider of large, small- and micro-cap independent investment research, today initiated coverage on Encorium Group, Inc. (Nasdaq:ENCO). Liberty Analytics is currently offering a complimentary trial subscription. To view our research, go to: www.libertyanalyticsco.com .

About LAC:

Liberty Analytics Co. is a leading provider of independent investment research in North America. Our services include research analysis on the large, small- and micro-cap markets, real-time news and financial data, market commentary and the LAC newsletter. Liberty Analytics' staff of large and small-cap investment professionals is dedicated to providing the market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.libertyanalyticsco.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.libertyanalyticsco.com/signup.php.

About Encorium Group, Inc. (Nasdaq:ENCO)

Encorium Group, Inc. (Nasdaq:ENCO) is a clinical research organization (CRO), which is engaged in the design and management of clinical trials for the pharmaceutical, biotechnology and medical device industries.

LAC Disclosure:

Libertyanalyticsco.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Liberty Analytics has not been compensated by any of the above-mentioned companies. Please read our report and visit our Web site, www.libertyanalyticsco.com, for complete risks and disclosures.

CONTACT: Liberty Analytics

Kevin Mix

480-626-1850

info@libertyanalyticsco.com

califax

03/31/10 6:18 AM

Post #92

BARCHART -

http://quote.barchart.com/texpert.asp?sym=enco&code=BSTK

Composite Indicator
Trend Spotter TM Buy

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Sell
20 Day Bollinger Bands Buy

Short Term Indicators Average: 60% - Buy
20-Day Average Volume - 506155

Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Sell
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 50% - Buy
50-Day Average Volume - 217461

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Sell

Long Term Indicators Average: 33% - Buy
100-Day Average Volume - 134737

Overall Average: 56% - Buy

Price Support Pivot Point Resistance
3.28 0.66 3.56 6.46

Scott12

03/30/10 11:49 PM

Post #91

Re: #90: @petermic - I'm not familiar with ENCO particularly, but I

I believe you are correct about the daytraders playing these low floaters. My only advice would be to just be careful playing them. They can drop just as fast!
Gl.

petermic

03/30/10 9:08 PM

Post #90

Re: #89: @airbus300 - I bought before the reverse split. $5

I'm not familiar with ENCO particularly, but I do trade every day these momo stocks.

Lately there has been a mania for low float, low priced stocks. Any excuse will do. Chat rooms get together and together they produce a run-up.

A whole bunch of stocks have gone up crazily just lately - ABIO, VIFL, SCKT, OBCI, et al. I believe it's mainly the daytrader chatrooms making it happen. I've seen it in the past as well.

airbus300

03/30/10 7:29 PM

Post #89

Re: #88: @Scott12 - I hope you guys locked in your profits.

I bought before the reverse split. $5 to break-even. It is certainly being manipulated. 9 million volume per day on only 3 million outstanding. I do not have a lot riding on this one, but could see the share price manipulated up to $20. Laugh if you want.

Scott12

03/30/10 7:14 PM

Post #88

Re: #86: @airbus300 - My guess is because over 4 million shares

I hope you guys locked in your profits. My guess is it will be back under 2 bucks before the week's out.
Good luck!

airbus300

03/30/10 12:41 PM

Post #86

Re: #85: @petermic - Do you guys have any theories as to

My guess is because over 4 million shares have traded today on a stock that only has 3 million shares outstanding.

petermic

03/30/10 12:01 PM

Post #85

Re: #83: @5cap - yahoo, I'm out at $4.40 and a happy

Do you guys have any theories as to why ENCO is up so much today? I'm new to the stock - can't find news or the yahoo message board.

Thanks

califax

03/30/10 9:50 AM

Post #84

... BUYOUT or something like this!

unbeliveable

5cap

03/30/10 9:45 AM

Post #83

Re: #82: @califax - ???

yahoo, I'm out at $4.40 and a happy camper. Want the moderator job back?

califax

03/30/10 9:39 AM

Post #82

???

califax

03/30/10 4:26 AM

Post #81

Encorium is present at World Vaccine Congress Washington DC on 19th – 22nd of April 2010.

Please visit our Vaccine page at: www.encorium.com/vaccines

http://www.terrapinn.com/2010/wvcdc/index.stm

Gold Sponsor: i.e. ENCORIUM
http://www.terrapinn.com/2010/wvcdc/confspon.stm

Speakers
http://www.terrapinn.com/2010/wvcdc/speakerList.stm

... Dr George Lautscham,
Director Business Development, Encorium

Older

Encorium Group Inc (fka ENCO)

Followers	5	Posters	30
Posts (Today)	0	Posts (Total)	131
Created	09/09/09	Type	Free
Moderators

Encorium Group, Inc. designs and manages clinical trials for pharmaceutical, biotechnology, and medical device industries primarily in Europe.

The company's clinical research and development services supporting Phase I through Phase IV clinical trials include data management, such as CRF review and tracking, data entry, clinical/statistical reports, and writing manuscripts for publication; and biostatistics for the use of professionals to develop and review protocols, design analysis plans, and report formats in various phases of drug development.

Its services also include strategic trial planning; project management; medical writing; quality assurance and compliance, such as investigator audits, pre-submission protocol compliance audits, and GCP audits; outsourcing clinical staff; and clinical trials management comprising case report form design, investigator recruitment, patient enrollment, and study monitoring and data collection.

In addition, Encorium's services include study protocol design; medical and regulatory affairs, such as regulatory strategy formulation, new drug and biologic license application document preparation and review, and quality assurance and liaison; pharmacovigilance; compliance and medical report writing; patient registries; and medical device certification.

It also licenses Oracle Clinical and Datafax as its clinical trials management systems.

Encorium offers clinical trial services in various therapeutic areas, such as cardiovascular, nephrology, endocrinology/metabolism, hematology, diabetes, neurology, oncology, immunology, vaccines, infectious diseases, gastroenterology, dermatology, hepatology, rheumatology, urology, ophthalmology, women's health, and respiratory medicine.

It was formerly known as Covalent Group, Inc. and changed its name to Encorium Group, Inc. in October 2006 in connection with the acquisition of Remedium Oy. The company was founded in 1989 and is headquartered in Wayne, Pennsylvania.